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passaged for a prolonged period of time in culture, undergoes a
non-clonal change reflected in lower ERK activity, increased p38
activity and a dormant/quiescent phenotype in vivo (D-HEp3).
When inoculated in vivo 80% of D-HEp3 cells rapidly arrest
in G0/G1 by day 6 after inoculation and remain dormant for sev-
eral months. We also found that activated p38 establishes a neg-
ative feedback loop to ERK and that blocking of p38 by genetic
or pharmacological inhibitors restores ERK activation and inter-
rupts tumor dormancy in vivo. These studies implicated high
p38 activity in the induction of dormancy in vivo. While p38 is
known to induce growth arrest and/or apoptosis, there is also
evidence indicating that in some instances, p38 signaling can
promote cell survival. However, knowledge of the proximal tar-
gets of p38 that underlie the p38-dependent dormancy program,
in particular the balance between cell proliferation and cell
death, have not been identified. We now show that p38 regu-
lates the activation of the endoplasmic reticulum (ER)-stress
activated kinase PERK and expression of the ER chaperone BiP/
Grp78. Regulation by p38 of these pathways allows dormant
tumor cells to not only become dormant but also resist drug-
toxicity. Increased activation of the eIF2a kinase PERK, results
in upregulation of ATF4 and activation of GADD153 promoter.
RNAi and dominant negative expression studies revealed that
both BiP and PERK promote survival and drug-resistance of dor-
mant cells and that BiP upregulation prevents Bax activation.
Further, genetic experiments showed that activation of the
PERK-eIF2a pathway is important for the maintenance of dor-
mancy. We propose that stress-dependent activation of p38 that
results in BiP upregulation and PERK activation may represent a
novel growth arrest and survival mechanism that induces dor-
mancy and protects dormant tumor cells from stress-insults
such as chemotherapy.
doi:10.1016/j.ejcsup.2006.04.009
S9. ZNF306, A NOVEL ZINC FINGER TRANSCRIPTION FACTOR,
DRIVES COLON CANCER PROGRESSION – AN ALTERNATE
GENETIC PATHWAY IN TUMOR PROGRESSION?
L. Yang, S. Hamilton, E. Ellis, A.M. Sanguino, G. Lopez-Berestein,
D.D. Boyd. Cancer Biology, Box 173, MD Anderson Cancer Center,
Houston, TX 77030, USA.
Colorectal cancer is the second leading cause of cancer deaths in
western countries. Although inactivation of the APC and p53
tumor suppressor genes coupled with Kirsten-Ras oncogene acti-
vation contribute to colon carcinogenesis, simultaneous muta-
tion of these three genes is rare suggesting alternate genetic
pathways leading to colon tumorigenesis/progression. To iden-
tify novel genes that contribute to colon cancer development/
progression we ‘‘data-mined’’ genes aberrantly expressed in
colorectal cancer using SAGE and UniGene Cluster Expression
analysis and identified, a novel Scan domain-containing zinc fin-
ger protein (ZNF306) whose expression is elevated in colon can-
cer. RT-PCR analysis of resected colon cancers showed elevated
ZNF306 mRNA levels in two thirds of tumors compared with
paired adjacent non-malignant tissue. Stable expression of the
cloned ZNF 306 cDNA in HCT 116 colon cancer cells yielded
enhanced soft agar colony formation, anoikis resistance and
resistance to 5-flurouracil when compared with cells bearing
the empty vector. More importantly, orthotopic implantation of
ZNF306-overexpressing HCT 116 cells yielded large tumors in
100% of the mice compared with vector only-expressing cells
which produced smaller tumors with a lower penetrance (20%
of mice). Conversely, transduction of two independent colon
cancer cell lines with a-ZNF306 siRNA reduced mRNA levels,
diminished colony size and attenuated cell proliferation. Fur-
ther, in vivo delivery of neutral liposomal-encapsulated siRNA
targeting ZNF306 reduced orthotopic growth of HCT116-ZNF306
cells. Flag-tagged expressed ZNF306 was nuclear-localized and
since zinc finger-containing proteins recognize DNA site-specific
sequences, we hypothesized that ZNF306 is a transcription fac-
tor. Cyclic amplification and selection of targets (CAST-ing) using
a random oligonucleotide library identified the KRKGGGG nucle-
otide sequence as a putative DNA binding site. Expression profil-
ing studies revealed several candidate downstream targets of
ZNF306 including VEGF and integrin b4, implicated in angiogen-
esis and Ras/PI3-kinase signaling, respectively. Over-expression
of these two putative targets was confirmed by RT-PCR. Addi-
tionally, increased CD31 (endothelial cells) immunoreactivity in
the ZNF306-over-expressing orthotopic tumors indicated aug-
mented angiogenesis. Both genes contained ZNF306 binding
sites in their regulatory sequences and chromatin immunopre-
cipitation assays and EMSA, using an anti-ZNF306 antibody we
generated, demonstrated binding of the ZNF306 protein to its
recognition sequence (identified by CAST-ing) in the VEGF pro-
moter indicating this gene to be a direct target of ZNF306.
Immunohistochemistry employing the anti-ZNF306 antibody
showed increased ZNF306 protein in colon cancer tissues com-
pared with adjacent non-malignant mucosa. In conclusion, we
have discovered a novel zinc finger protein, ZNF306 that contrib-
utes to colon cancer progression in part by elevating VEGF and
integrin b4 expression. We propose that this gene product repre-
sents a key protein in an alternate genetic pathway leading to
colon cancer progression.
doi:10.1016/j.ejcsup.2006.04.010
S10. SPECIFIC TRANSCRIPTIONAL REGULATORS OF THE u-PAR
GENE – IN VIVO AND CLINICAL RELEVANCE, AND FIRST
SUGGESTIONS FOR MOLECULAR TUMOR STAGING
Heike Allgayer. Department of Experimental Surgery/Molecular
Oncology of Solid Tumors (Collaboration Unit German Cancer Research
Center-DKFZ-Heidelberg), Universita¨tsklinikum Mannheim, Ruprecht-
Karls-University Heidelberg, Mannheim, Germany.
The urokinase-receptor (u-PAR) promotes the invasive and meta-
static phenotype and has been shown to be associated with early
relapse and poor prognosis in enumerous types of cancers. From
our and other studies we know that high u-PAR gene expression
in carcinoma cells is largely due to the transcriptional regulation
of the gene. We have characterized two cis-elements (152/135,
bound with an AP-2-like protein, Sp1, and Sp3; 190/171, bound
with AP-1-transcription factors) of the u-PAR promoter which are
decisive for diverse means of u-PAR-gene expression in highly
invasive colon cancer cells, among them being constitutive,
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PMA-induced, K-ras- and Src-induced gene expression. New data
will be presented in this lecture showing that the newly character-
ized tumor suppressor Pdcd4 suppresses u-PAR gene expression,
this again in part being mediated by Sp3 bound to the 152/
135 motif.
Furthermore, the lecture will focus on the differential binding
of transcription factors to both u-PAR promoter elements in vivo,
having been investigated in a large series of resected tumor and
normal tissue of colorectal and gastric cancer patients. We will
demonstrate that, depending on the transcription factor and cis-
element, patient subgroups of different size can be selected in
which transactivation via these promoter elements might be
tumor-tissue-specific, suggesting subgroups for tumor-selective
targeting. Also, the lecture will outline that different u-PAR-pro-
moter motifs may be of different tumor-specificity in vivo. We will
also suggest patient subgroups in which a synergistic regulation
of u-PAR gene expression in resected tissues via both promoter
elements can be postulated. Finally, first data on a clinical-prog-
nostic relevance of differential transcription factor binding to
specific u-PAR-promoter motifs will be shown, suggesting the
binding of, for example, Sp1, and transcription factor combina-
tions out of Sp1/AP-2 and AP-1-binding as new and independent
predictors of disease-specific survival. A first molecularly
extended staging model will be presented from these data. Poten-
tial conclusions for a more target-oriented patient selection and
therapy out of transcriptional and oncogeneic regulators of the
uPA-R gene will be discussed.
doi:10.1016/j.ejcsup.2006.04.011
S11. uPA AND PAI-1: CLINICALLY AND TECHNICALLY
VALIDATED PROGNOSTIC MARKERS IN BREAST CANCER
M.J. Duffy. St Vincent’s University Hospital, Dublin, Ireland.
For optimum management of patients with cancer, accurate
prognostic factors are required. The primary determinant of out-
come in patients with malignancy is cancer progression, espe-
cially the formation of distant metastases. Based on data from
model systems, urokinase plasminogen activator (uPA) is one of
the critical mediators of cancer progression. uPA appears to
mediate progression via multiple mechanisms including remod-
elling of the extracellular matrix, enhancing cell proliferation
and migration and modulating cell adhesion. PAI-1, although
originally identified as an inhibitor of uPA, is also causally
involved in cancer progression. Consistent with their roles in
cancer progression, multiple independent studies have shown
that elevated levels of uPA and PAI-1 predict poor prognosis in
patients in breast cancer. The prognostic impact of uPA and
PAI-1 is potent (e.g., RR > 2.0), independent of standard prognostic
factors and found in both lymph node-negative and lymph node-
positive disease. Importantly, the prognostic impact of uPA/PAI-1
has been validated in both a randomized prospective trial and a
pooled analysis, i.e., in 2 level I evidence studies. In addition to
clinical validation, specific ELISA for uPA and PAI-1 have under-
gone technical validation including validation in an external
quality assurance program. uPA and PAI-1 are thus now ready
for clinical application, especially in the identification of newly
diagnosed breast cancer patients that may be able to avoid hav-
ing to receive adjuvant chemotherapy.
doi:10.1016/j.ejcsup.2006.04.012
S12. EXPRESSION OF MARKERS OF INVASION AND
PROGRESSION – COMPARING MOLECULAR DETERMINANTS
WITH PHENOTYPES
Rainer Grobholz. Department of Pathology, University Hospital
Mannheim, Ruprecht-Karls-University Heidelberg, Theodor-Kuzuer-
Ufer 1-3, D-68167 Mannheim, Germany.
Cancer cells usually have a distinct morphological and genetic
profile that allows to determine between reactive, premalignant
and malignant lesions. In some tumor entities, however, morpho-
logical and expression profiles do not necessarily reflect the true
nature of the putative lesion. Molecular biological advances could
further clarify the biological potential in some tumor entities, in
others however, morphological and topographical criteria are still
crucial, since no evident typical molecular profiles could be deter-
mined so far.
Prostate cancer is a prominent example of cancer where exo-
crine and neuroendocrine (NE) tumor cells can occur within the
same tumor. The role of these NE cells is still under debate, even
the question of its neoplastic nature and its biological signifi-
cance. Since in these NE cells no proliferation could be demon-
strated so far, NE tumor cells in prostate cancer are regarded as
post-mitotic and their significance has been regarded as ‘low’.
The interesting question is, therefore, whether a post-mitotic
cancer cell still deserves the attribute ‘‘cancer cell’’ and what
are its biological functions in the cancerous orchestration.
Although molecular and clinical data seem to give evidence that
NE tumor cells are the result of a transdifferentiation process
and possess a prognostic significance, their final role in vivo is
not yet completely understood.
doi:10.1016/j.ejcsup.2006.04.013
S13. MOLECULAR MECHANISMS OF MATRIX
METALLOPROTEINASE (MT-MMP) INDUCTION OF CANCER
CELL MIGRATION AND METASTASIS
Stanley Zucker, Jian Cao. Stony Brook University, Stony Brook, NY
11794, United States; Veterans Affairs Medical Center, Northport, NY
11768, United States.
Matrix metalloproteinases (MMPs) are important in cancer dis-
semination by virtue of degradation of extracellular matrix, as
well as diverse effects on cell growth, apoptosis, migration,
and angiogenesis. Negative results from clinical drug trials of
MMP inhibitors in advanced cancers has refocused attention
on the role of MMPs in early cancer development. Experimental
and clinical evidence suggests that membrane type 1-matrix
metalloproteinase (MT1-MMP) may serve as a master regulator
of cancer progression. The mechanism underlying this process
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